229 related articles for article (PubMed ID: 16450374)
1. High antineoplastic activity of new heterocyclic compounds in cancer cells with resistance against classical DNA topoisomerase II-targeting drugs.
Lage H; Aki-Sener E; Yalcin I
Int J Cancer; 2006 Jul; 119(1):213-20. PubMed ID: 16450374
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of terpenoids against classical and atypical multidrug resistant cancer cells.
Lage H; Duarte N; Coburger C; Hilgeroth A; Ferreira MJ
Phytomedicine; 2010 May; 17(6):441-8. PubMed ID: 19682879
[TBL] [Abstract][Full Text] [Related]
3. Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells.
Lage H; Dietel M
J Cancer Res Clin Oncol; 2002 Jul; 128(7):349-57. PubMed ID: 12136248
[TBL] [Abstract][Full Text] [Related]
4. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK
Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730
[TBL] [Abstract][Full Text] [Related]
5. Phenolic compounds as selective antineoplasic agents against multidrug-resistant human cancer cells.
Duarte N; Lage H; Abrantes M; Ferreira MJ
Planta Med; 2010 Jul; 76(10):975-80. PubMed ID: 20157880
[TBL] [Abstract][Full Text] [Related]
6. Triterpenoids from Momordica balsamina with a Collateral Sensitivity Effect for Tackling Multidrug Resistance in Cancer Cells.
Ramalhete C; Mulhovo S; Lage H; Ferreira MU
Planta Med; 2018 Dec; 84(18):1372-1379. PubMed ID: 29996165
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.
My Van HT; Woo H; Jeong HM; Khadka DB; Yang SH; Zhao C; Jin Y; Lee ES; Youl Lee K; Kwon Y; Cho WJ
Eur J Med Chem; 2014 Jul; 82():181-94. PubMed ID: 24904965
[TBL] [Abstract][Full Text] [Related]
8. SH-7, a new synthesized shikonin derivative, exerting its potent antitumor activities as a topoisomerase inhibitor.
Yang F; Chen Y; Duan W; Zhang C; Zhu H; Ding J
Int J Cancer; 2006 Sep; 119(5):1184-93. PubMed ID: 16570288
[TBL] [Abstract][Full Text] [Related]
9. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
[TBL] [Abstract][Full Text] [Related]
10. Jatrophane diterpenes and cancer multidrug resistance - ABCB1 efflux modulation and selective cell death induction.
Reis MA; Ahmed OB; Spengler G; Molnár J; Lage H; Ferreira MJ
Phytomedicine; 2016 Aug; 23(9):968-78. PubMed ID: 27387405
[TBL] [Abstract][Full Text] [Related]
11. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
12. [Expression of DNA topoisomerases (I, II alpha, II beta) mRNA in etoposide- and mAMSA-resistant cell lines].
Matsumoto Y; Takano H; Nagao S; Iglesias A; Fojo T
Gan To Kagaku Ryoho; 1997 Dec; 24(15):2265-9. PubMed ID: 9422071
[TBL] [Abstract][Full Text] [Related]
13. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines.
Sugimoto Y; Tsukahara S; Oh-hara T; Liu LF; Tsuruo T
Cancer Res; 1990 Dec; 50(24):7962-5. PubMed ID: 2174738
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
[TBL] [Abstract][Full Text] [Related]
15. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
Oloumi A; MacPhail SH; Johnston PJ; Banáth JP; Olive PL
Cancer Res; 2000 Oct; 60(20):5747-53. PubMed ID: 11059769
[TBL] [Abstract][Full Text] [Related]
16. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype.
Matsumoto Y; Takano H; Fojo T
Cancer Res; 1997 Nov; 57(22):5086-92. PubMed ID: 9371507
[TBL] [Abstract][Full Text] [Related]
17. Insight into eukaryotic topoisomerase II-inhibiting fused heterocyclic compounds in human cancer cell lines by molecular docking.
Taskin T; Yilmaz S; Yildiz I; Yalcin I; Aki E
SAR QSAR Environ Res; 2012; 23(3-4):345-55. PubMed ID: 22490049
[TBL] [Abstract][Full Text] [Related]
18. Selection and characterization of heat-resistant variants of multidrug-resistant human gastric carcinoma cell lines.
Jordan A; Scholz R
Exp Oncol; 2005 Mar; 27(1):18-23. PubMed ID: 15812352
[TBL] [Abstract][Full Text] [Related]
19. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M
Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812
[TBL] [Abstract][Full Text] [Related]
20. Adva-27a, a novel podophyllotoxin derivative found to be effective against multidrug resistant human cancer cells.
Merzouki A; Buschmann MD; Jean M; Young RS; Liao S; Gal S; Li Z; Slilaty SN
Anticancer Res; 2012 Oct; 32(10):4423-32. PubMed ID: 23060568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
